Sanofi Q2 FY26 business EPS rises 33.3% to €2.09; net sales climb 17.8% to €11.6 billion

Sanofi reported Q2 FY26 results with business EPS rising 33.3% to €2.09 and net sales climbing 17.8% to €11.6 billion. While IFRS metrics declined due to specific adjustments, core performance was strong, driven by a 37.6% surge in Dupixent sales. The company raised its 2026 guidance, projecting around 10% net sales growth and slightly faster business EPS expansion.

Sanofi Q2 net sales rose 16% to €11.6 billion, while IFRS net income fell 91.3% to €343 million. * IFRS EPS dropped 91% to €0.29; business EPS climbed 31.4% to €2.09. * Dupixent sales increased 37.6% to €5.2 billion; vaccines sales declined 4.7% to €1.1 billion on a tough flu comparison. * Pharma launches sales jumped 48.3% to €1.3 billion; R&D expenses rose 17.9% to €2.2 billion. * 2026 guidance was raised, with net sales now seen growing around 10% and business EPS expected to grow slightly faster. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300130PRIMZONEFULLFEED1001255118) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Sanofi Q2 net sales rose 16% to €11.6 billion, while IFRS net income fell 91.3% to €343 million. * IFRS EPS dropped 91% to €0.29; business EPS climbed 31.4% to €2.09. * Dupixent sales increased 37.6% to €5.2 billion; vaccines sales declined 4.7% to €1.1 billion on a tough flu comparison. * Pharma launches sales jumped 48.3% to €1.3 billion; R&D expenses rose 17.9% to €2.2 billion. * 2026 guidance was raised, with net sales now seen growing around 10% and business EPS expected to grow slightly faster. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300130PRIMZONEFULLFEED1001255118) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)